Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Terns Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +11 vs. Q3 2023
- Shares held
- 63.6M
- +2.59M (+4.2%) vs. Q3 2023
- Total value
- $412.7M
- +$105.9M (+34.5%) vs. Q3 2023
- New holders
- 26
- 33 more added
- Sold out
- 15
- 22 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TERN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $75.4K |
| Q1 2026 | 317 | $6.56B |
| Q4 2025 | 248 | $4.95B |
| Q3 2025 | 141 | $665.7M |
| Q2 2025 | 130 | $310.0M |
| Q1 2025 | 138 | $229.4M |
| Q4 2024 | 157 | $477.2M |
| Q3 2024 | 156 | $663.1M |
| Q2 2024 | 126 | $446.7M |
| Q1 2024 | 112 | $414.8M |
| Q4 2023 | 103 | $412.7M |
| Q3 2023 | 93 | $310.4M |
| Q2 2023 | 103 | $505.0M |
| Q1 2023 | 79 | $630.2M |
| Q4 2022 | 65 | $506.2M |
| Q3 2022 | 45 | $178.1M |
| Q2 2022 | 42 | $36.5M |
| Q1 2022 | 44 | $50.0M |
| Q4 2021 | 37 | $116.7M |
| Q3 2021 | 34 | $174.3M |
| Q2 2021 | 36 | $203.8M |
| Q1 2021 | 42 | $393.7M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Terns Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 6,100,000 | $39.6M | 1.39% | +100,000+1.7% | Added |
| Vivo Capital, LLC | 6,657,992 | $43.2M | 3.54% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 7,619,135 | $49.4M | 0.99% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −571,265−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −290,100−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −135,015−100.0% | Sold out |
| Polar Asset Management Partners Inc. | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −82,978−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −67,957−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −45,028−100.0% | Sold out |
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −41,728−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −33,055−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −31,695−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −27,500−100.0% | Sold out |
| PEAK6 Investments LLC | 0 | $0 | 0.00% | −19,097−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −17,014−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −13,849−100.0% | Sold out |
| Kovack Advisors, Inc. | 0 | $0 | 0.00% | −10,200−100.0% | Sold out |
| Decheng Capital Management III (Cayman), LLC | – | – | – | – | Not filed |